Benitec delays HIV/AIDS drug IND filing
Tuesday, 31 January, 2006
Gene therapy company Benitec's (ASX:BLT) shares fell on news that the US FDA investigational new drug (IND) filing for its HIV/AIDS therapeutic will be delayed.
The company said that the delay was due to one aberrant result in the release tests of the clinical materials, not the drug itself.
"We are working closely with the manufacturing team to resolve this unanticipated result and will move forward as quickly as possible with the IND filing," said Benitec's CEO Sara Cunningham in a statement. "Although the result is unrelated to the safety or efficacy of the drug, we will not file the IND until we are certain that all components of the clinical materials are fully and properly characterised and pass our stringent manufacturing criteria."
Benitec's shares were trading at $0.165 at the time of writing, down 8.3 per cent from $0.18 when trade opened this morning.
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
